CLINICAL_TRIALS
trial_result
· 2014-06-02
Clinical Trial Update: Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study [Phase 2]
Summary
A Phase 2 trial of Desoximetasone Spray 0.25% for psoriasis completed, with results posted to evaluate safety related to HPA axis function.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2014-06-02